BAMCO Inc
SPRY icon

BAMCO Inc’s ARS Pharmaceuticals SPRY Stock Holding History

BAMCO Inc’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Buy
1,273,341
+4,809
+0.4% +$46.1K 0.03% 227
2025
Q4 		$14.8M Hold
1,268,532
– – 0.04% 214
2025
Q3 		$12.7M Buy
1,268,532
+1,228,532
+3,071% +$17.6M 0.03% 227
2025
Q2 		$698K Buy
+40,000
New +$577K ﹤0.01% 297

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BAMCO Inc's SPRY Position: Q1 2026 in Review

BAMCO Inc increased its ARS Pharmaceuticals (SPRY) stake by 0.38% in Q1 2026, buying an estimated $46.1K and bringing the position to 1,273,341 shares worth $10.2M. The position accounts for 0.03% of the portfolio, ranked #227.

BAMCO Inc first reported a position in SPRY in Q2 2025 and has held it in 4 quarters since. The position peaked at $14.8M in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • BAMCO Inc held 1,273,341 shares of ARS Pharmaceuticals worth $10.2M as of Q1 2026.
  • BAMCO Inc bought 4,809 ARS Pharmaceuticals shares in Q1 2026, an estimated $46.1K.
  • ARS Pharmaceuticals made up 0.03% of BAMCO Inc's portfolio in Q1 2026, its #227 holding.
  • BAMCO Inc first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • BAMCO Inc's ARS Pharmaceuticals position peaked at $14.8M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on BAMCO Inc's 13F filing for Q1 2026, filed 15 May 2026.